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Abstract: Staphylococcus aureus and Staphylococcus epidermidis are considered two of the most important
pathogens, and their biofilms frequently cause device-associated infections. Microbial biosurfactants
recently emerged as a new generation of anti-adhesive and anti-biofilm agents for coating implantable
devices to preserve biocompatibility. In this study, R89 biosurfactant (R89BS) was evaluated as an
anti-biofilm coating on medical-grade silicone. R89BS is composed of homologues of the mono- (75%)
and di-rhamnolipid (25%) families, as evidenced by mass spectrometry analysis. The antimicrobial
activity against Staphylococcus spp. planktonic and sessile cells was evaluated by microdilution and
metabolic activity assays. R89BS inhibited S. aureus and S. epidermidis growth with minimal inhibitory
concentrations (MIC99) of 0.06 and 0.12 mg/mL, respectively and dispersed their pre-formed biofilms up
to 93%. Silicone elastomeric discs (SEDs) coated by R89BS simple adsorption significantly counteracted
Staphylococcus spp. biofilm formation, in terms of both built-up biomass (up to 60% inhibition at
72 h) and cell metabolic activity (up to 68% inhibition at 72 h). SEM analysis revealed significant
inhibition of the amount of biofilm-covered surface. No cytotoxic effect on eukaryotic cells was
detected at concentrations up to 0.2 mg/mL. R89BS-coated SEDs satisfy biocompatibility requirements
for leaching products. Results indicate that rhamnolipid coatings are effective anti-biofilm treatments
and represent a promising strategy for the prevention of infection associated with implantable devices.
Keywords: biofilm; biosurfactants; Staphylococcus spp.; antimicrobial; anti-adhesive; anti-biofilm;
biomaterials; silicone; medical devices
1. Introduction
Given their effectiveness in improving patient health and quality of life, the use of implantable
medical devices significantly increased over the years. Unfortunately, they can also act as a substrate for
microbial colonization and biofilm development. In particular, approximately 60–70% of nosocomial
Molecules 2019, 24, 3843; doi:10.3390/molecules24213843 www.mdpi.com/journal/molecules
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infections are due to the development of microbial biofilms at the interface between the implanted
device and tissues. [1]. Biofilms are defined as microbial communities derived from cells irreversibly
attached to one another or to a substrate, embedded in a matrix of extracellular polymeric substances [2].
In this “lifestyle”, bacteria have slower metabolism, are more resistant to the host’s immune system,
and are more tolerant to drug therapy than their planktonic counterparts [3,4].
Staphylococcus aureus and Staphylococcus epidermidis, due to their ability to form biofilms,
are considered two of the most relevant pathogens in device-associated infections [5], affecting mainly
hospitalized patients, immunocompromised or immunosuppressed subjects, and premature babies [6,7].
These Gram-positive bacteria are mainly introduced into the body during the surgical implantation of
the device, thereby increasing the risk of surgical site contamination and implant colonization [5,8].
Implant colonization and subsequent biofilm formation often lead to the loss of device functionality
and may represent a way to colonize new suitable sites. Surgical removal and replacement of the
infected device is the most effective eradication strategy. However, this is not always applicable,
and suppressive long-term multi-drug antibiotic therapies should be administered [9,10].
Several surface-treated biomaterials and medical devices with anti-biofilm properties were
proposed [11–19], but most of them showed either potential toxicity to the peri-implant tissue cells
or limited efficacy in clinical practice over time [20]. Therefore, new safe and effective approaches to
prevent and treat biofilm infections are urgently required. The development of biocompatible coatings
with antibacterial and/or anti-adhesive molecules represents one of the most promising approaches to
reduce the incidence of implant-related infections [21].
Microbial biosurfactants (BSs) recently emerged as a new generation of “green” anti-biofilm and
antimicrobial agents with enhanced biocompatibility [22–27].
Among microbial BSs, rhamnolipids from Pseudomonas aeruginosa showed relevant anti-biofilm potential
in the medical field thanks to their antibacterial, anti-adhesive, and anti-biofilm properties [28–30].
The present study aimed at evaluating the antimicrobial activity and anti-biofilm properties
of rhamnolipid R89, from P. aeruginosa 89. The antibacterial properties of the biosurfactant against
planktonic cells of S. aureus and S. epidermidis were studied, as well as its effect on biofilm dispersal.
Experiments on medical-grade silicone coated with R89BS were conducted against intermediate
and mature staphylococcal biofilms. Results are discussed taking into consideration the R89BS
chemistry, the physicochemical characteristics of the R89BS-coated surfaces, and the cytotoxicity of the
biosurfactant and of the R89BS-coated silicone discs.
2. Results
2.1. Chemical Characterization of R89BS
The negative electrospray ionization (ESI) MS analysis of the crude biosurfactant R89BS extract
showed the presence of homologues of mono- and di-rhamnolipids (Figure 1). The mono-rhamnolipid
family members were composed mainly of C10–C10, C8–C10, and C10–C12, homologues, whose structures
were confirmed by the product ion spectra of the precursor molecules [M − H]− at m/z 503, 475,
and 531 respectively. The di-rhamnolipid family members were represented by three main homologues
corresponding to C10–C8, C10–C10, and C10–C12 homologues, whose structures were confirmed by the
product ion spectra of the deprotonated molecules [M − H]− at m/z 621, 649, and 677, respectively.
The relative amounts of the two groups in the crude extract were about 75% mono- and
25% di-rhamnolipids.
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Figure 1. Negative electrospray ionization ((−)ESI) MS analysis (direct infusion) of rhamnolipids 
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rhamnolipids. The second set evidenced three main signals corresponding to the deprotonated 
molecules of di-rhamnolipids. 
2.2. Antimicrobial Tests on Planktonic Cells 
R89BS was checked as an antimicrobial agent on Staphylococcus spp. via the microdilution 
method. The effect of the crude R89 biosurfactant on the growth of planktonic cells of S. aureus ATCC®  
6538TM and S. epidermidis ATCC®  35984TM was similar. The results showed an antibacterial activity of 
R89BS against both Gram-positive strains with minimal inhibitory concentration (MIC) values of 0.06 
mg/mL and 0.12 mg/mL for S. aureus and S. epidermidis, respectively. The optical density values 
measured at 595 nm for the different R89BS concentrations are reported in Table 1. The corresponding 
percentages of inhibition, starting from the MICs determined visually, were 99.5%. 
Table 1. Effect of R89 biosurfactant (R89BS) on Staphylococcus spp. planktonic cells. Results are 
represented as means and standard deviations (SD). Minimal inhibitory concentration (MIC) values 
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 0.03 0.768 ± 0.065 
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 0.12 0.001 ± 0.004 
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2.3. Disruption of Pre-Formed Biofilms 
Figure 1. Negative electrospray ionization ((−)ESI) MS analysis (direct infusion) of rhamnolipids produced
by Pseudomonas aeruginosa 89. Two clusters of peaks revealed two sets of homologue molecules. The first
set evidenced three main signals corresponding to the [M −H]− of mono-rhamnolipids. The second set
evidenced three main signals corresponding to the deprotonated molecules of di-rhamnolipids.
2.2. Antimicrobial Tests o Planktonic Cells
R89BS was checked as an antimicrobial agent on Staphylococcus spp. via the microdilution method.
The effect of the crude R89 biosurfactant on the growth of planktonic cells of S. aureus ATCC® 6538TM
and S. epidermidis ATCC® 35984TM was simil r. The results showed an antibacterial activity of R89BS
against both Gram-positive strains with minimal inhibitory concentr tion (MIC) values of 0.06 mg/mL
and 0.12 mg/mL for S. aureus and S. epidermidi , respectively. The optical de sity v lu s measured at
595 nm for the different R89BS concentrations are reported in Table 1. The corresponding percentages
of inhibition, startin from the MICs determined visually, were ≥99.5%.
Table 1. Effect of R89 biosurfactant (R89BS) on Staphylococcus spp. planktonic cells. Results are
represented as means and standard deviations (SD). Minimal inhibitory concentration (MIC) values are
provided, as observed with the un ided eye. OD—optical density.
Test Strain R89BS Concentration (mg/mL) OD at 595 nm (n = 6) (mean ± SD)
S. aureus ATCC® 6538TM Ctrl 0.847 ± 0.013
0.03 0.772 ± 0.017
0.06 0.004 ± 0.006
0.12 0.001 ± 0.006
0.25 0.001 ± 0.006
S. epidermidis ATCC® 35984TM Ctrl 0.918 ± 0.039
0.03 0.768 ± 0.065
0.06 .630 ± 0.062
0.12 . 01 ± 0.0 4
0.25 0.001 ± 0.007
2.3. Disruption of Pre-Formed Biofilms
The ability of R89BS crude extract to influence the growth of Staphylococcus spp. pre-existing
biofilms was determined after 24 h of co-incubation. Absorbance at 570 nm versus R89BS concentration
is shown in Figure 2. R89BS significantly disrupted pre-formed biofilms of both Staphylococcus strains
in a concentration-dependent manner (p < 1 × 10−15). In particular, as confirmed by Tukey post hoc
Molecules 2019, 24, 3843 4 of 17
test, pre-formed biofilms were significantly dislodged by R89BS concentrations from 0.12 to 2 mg/mL
with biofilm reduction ranges of 68–89% for S. aureus and of 44–96% for S. epidermidis (p < 1 × 10−4).
Conversely, no significant biofilm disruption activity was detected for R89BS at the concentration of
0.06 mg/mL (p > 5 × 10−2).
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Figure 2. Staphylococcus spp. biofilm disruption by R89 biosurfactant (R89BS). S. aureus and S. epidermidis
pre-formed biofilms were co-incubated with R89BS at concentrations ranging from 0.06 to 2 mg/mL.
The disrupting activity of R89BS on Staphylococcus spp. biofilms was evaluated after 24 h at 37 ◦C. Dots
(six for each concentration) represent single experimental data.
2.4. Surface Physicochemical Characterization
Surface physicochemical characterization was carried out on control silicone elastomeric discs
(SEDs) (immersed in phosphate-buffered saline (PBS) only) and on SED samples incubated in R89BS
solution at a concentration of 2 mg/mL.
SED samples showed a hydrophobic behavior with an advancing contact angle of 112◦ ± 5◦ and a
receding angle of 81.0◦ ± 3.2◦. The wettability increased significantly on samples coated with R89BS,
settling on values of 84.4◦ ± 2.2◦ (advancing) and 72.2◦ ± 2.5◦ (receding), due to the introduction of
hydrophilic groups, such as –OH, –COOH, and –NH2 present in R89BS molecules. It is worth noting
that contact angle hysteresis in this case was quite small (about 12◦), indicating a quite homogeneous
distribution of the surfactant on the surface.
ATR-FTIR analysis was performed to study changes in the compositional properties at the surface
of SED samples after R89BS adsorption. Figure 3 compares spectra of uncoated and R89BS-coated SED
samples. The SED spectrum showed characteristic bands at 800–1110 cm−1 due to Si–O–Si stretching,
at 1258 cm−1 due to CH3 symmetric stretching of Si–CH3, at 1412 cm−1 due to CH3 asymmetric
stretching of Si–CH3, and at 2962.3 cm−1 due to C–H stretching [31]. After R89BS adsorption, a band
appeared at 1735 cm−1, attributable to carbonyl (C=O) stretching, which is characteristic of the ester
functional group of the rhamnolipid.
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2.5. Anti-Biofilm Assay
2.5.1. Biofilm Quantification
The anti-biofilm activity of R89BS-coated SEDs against biofilm growth of Staphylococcus spp.
on SEDs was detected up to 72 h of biofilm development (Figure 4). S. aureus biofilm was equally
inhibited in terms of total biomass (Figure 4A) and cell metabolic activity (Figure 4B). For S. epidermidis,
the biofilm was mostly reduced in terms of the metabolic activity of microbial cells (Figure 4B) rather
than in terms of total biomass (Figure 4A).
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Figure 4. Anti-biof lm activity of R89BS deposited on the surface of silicone discs (SEDs) by direct physical
adsor tion. The anti-biofilm activity of R89BS-coated SEDs n Staphyloc ccus spp. biofilm format on was
evaluated in terms of both biofilm biomass (A) and cell etabolic activity (B) after 24, 48, and 72 h.
For both strains, two-way ANOVA confirmed that biofilm biomass and metabolic activity were
significantly dependent on the SED treatment (p < 1 × 10−15) and incubation time (p < 1 × 10−15).
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The efficacy of R89BS-coated SEDs against S. aureus biofilm formation was stable up to 48 h and
decreased in part only at 72 h. In the case of S. epidermidis, the anti-biofilm activity of the R89BS
coating reduced over time. Table 2 summarizes the 95% confidence intervals and p-values obtained
for the tested Staphylococcus spp. in terms of both total biofilm biomass and cell metabolic activity.
Overall, the pre-treatment of silicone surfaces with R89BS resulted in a biofilm inhibition of 76% for S.
aureus and of 63% for S. epidermidis with respect to uncoated control SEDS. Details of percentages of
biomass and metabolic activity inhibitions at the different time points are indicated in Table 3.
Table 2. The 95% confidence intervals and p-values calculated for Staphylococcus spp. biofilm total
biomass and cell metabolic activity in pre-coating assays. Ctrl—control.
Time (h) Strain
Total Biomass Cell Metabolic Activity
95% Confidence
Interval for the
Ratio Ctrl/R89BS
p-Value
(t-Test)
95% Confidence
Interval for the
Ratio Ctrl/R89BS
p-Value
(t-Test)
24 S. aureus (4.33, 5.35) 1.50 × 10−7 (3.65, 5.35) 4.77 × 10−6
S. epidermidis (2.65, 3.04) 2.22 × 10−8 (3.65, 4.36) 1.09 × 10−7
48 S. aureus (4.50, 5.10) 2.28 × 10−10 (3.95, 4.89) 3.27 × 10−8
S. epidermidis (2.30, 2.54) 3.63 × 10−9 (2.83, 3.10) 4.30 × 10−11
72 S. aureus (3.13, 3.49) 6.36 × 10−9 (3.29, 3.95) 4.22 × 10−10
S. epidermidis (1.95, 2.08) 6.43 × 10−11 (2.56, 2.88) 4.08 × 10−10
Table 3. Inhibition percentages of Staphylococcus spp. biofilm formation detected by CV and MTT
assays. Relative inhibitions in the percentage of biofilm-covered surface obtained from SEM analysis
are also reported.
Time (h) Strain Biomass (CV) Metabolic Activity(MTT)
Surface Coverage
(SEM)
24 S. aureus 79.2% 77.1% 69.9%
S. epidermidis 64.6% 74.9% 40.3%
48 S. aureus 79.1% 77.2% 81.4%
S. epidermidis 58.4% 66.2% 51.1%
72 S. aureus 69.6% 72.3% 78.0%
S. epidermidis 50.2% 63.1% 52.8%
In order to confirm that R89BS activity was due to an anti-biofilm and not antibacterial action,
the number of live cells was checked in the supernatant. For each treated and untreated SED, after 24,
48, and 72 h, growth media and washing solutions were collected. The presence of live bacteria
was evaluated by cell metabolic assay (MTT method). The absorbance values corresponding to the
supernatants of R89BS-coated SEDs were significantly higher in comparison to the obtained values for
the supernatants of control SEDs (p < 0.01) suggesting that, in the wells containing the treated discs,
vital cells lived in a planktonic state rather than forming a biofilm (Table 4).
Table 4. Mean absorbance values (A570) ± standard deviation obtained in the MTT assays for evaluation
of live cells in the supernatants of R89BS-coated silicone elastomeric discs (SEDs) and control SEDs at
the different time points.
Time (h)
S. aureus S. epidermidis
Control SEDs R89BS-Coated SEDs Control SEDs R89BS-Coated SEDs
24 h 3.06 ± 0.05 9.09 ± 0.19 18.74 ± 1.88 31.24 ± 4.05
48 h 7.73 ± 0.63 9.79 ± 0.62 37.90 ± 5.12 45.73 ± 3.38
72 h 8.47 ± 1.20 11.42 ± 1.58 51.09 ± 5.46 60.94 ± 2.86
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2.5.2. SEM Analysis of Bacterial Biofilms
SEM observation of the SED surface evidenced a marked difference in the amount, distribution,
and microstructure of the adhering microbial biofilm. Results of the quantitative analysis showed that
the S. aureus biofilm covered most of the surface of control SEDs within 24 h. A similar feature was
obtained for S. epidermidis within 48 h. Most importantly, the biofilm surface coverage was significantly
lower in R89BS-coated SEDs at all the considered time points. Quantitative results are summarized in
Figure 5.
Molecules 2019, 24, x 7 of 17 
 
Table 4. Mean absorbance values (A570) ± standard deviation obtained in the MTT assays for 
evaluation of live cells in the supernatants of R89BS-coated silicone elastomeric discs (SEDs) and 
control SEDs at the different time points. 
Time (h) 
S. aureus S. epidermidis 
Control SEDs R89BS-coated SEDs  Control SEDs R89BS-coated SEDs 
24 h 3.06 ± 0.05 9.09 ± 0.19 18.74 ± 1.88 31.24 ± 4.05 
48 h 7.73 ± 0.63 9.79 ± 0.62 37.90 ± 5.12 45.73 ± 3.38 
72 h 8.47 ± 1.20 11.42 ± 1.58 51.09 ± 5.46 60.94 ± 2.86 
2.5.2. SE  Analysis of Bacterial Biofilms 
SEM observation of the SED surface evidenced a arked ifference in the a ount, distrib tion, 
and microstructure of the adhering microbial biofilm. Results of the qu ntitative analysis showed 
that the S. aureus biofilm covered most of the surfa e of control SEDs within 24 h. A similar f ature 
was obtained for S. epidermidis within 48 h. Most importantly, the biofilm surface coverage was 
significantly lower in R89BS-coated SEDs at all the considered time points. Quantitative results are 
summarized in Figure 5. 
 
Figure 5. Quantitative evaluation of the biofilm surface coverage. Biofilm coverage surface was 
obtained by the analysis of a set of low-magnification SEM images obtained collecting a backscattered 
electron signal over a total surface of 29 mm2 at the SED center. R89BS-coated SEDs showed lower 
coverage values with respect to control SEDs, irrespectively of the incubation time points (24 h, 48 h, 
72 h) for both the tested Staphylococcus spp. 
Qualitative analysis at higher magnification confirmed that the S. aureus biofilm appeared more 
structured than that of S. epidermidis at 24 h in control SEDs. However, a three-dimensional 
architecture and extracellular matrix were present in all control samples (untreated SEDs) at 48 h and 
72 h of incubation. A marked three-dimensional architecture typical of a mature biofilm was evident 
for both S. aureus and S. epidermidis at 72 h on uncoated silicone discs. On the contrary, small and 
isolated aggregates of bacteria were identified at 24 h in R89BS samples for both strains. More 
structured aggregates were documented for S. aureus on treated SEDs at 48 h, showing elongated 
biofilm super-structures that increased in size at 72 h. In contrast, S. epidermidis on treated SEDs 
showed a more uniform cell distribution, with an increasing cell density at higher incubation times. 
The three-dimensional development of biofilms for both Staphylococcus strains was very limited on 
R89BS-coated surfaces. Typical features of a mature biofilm were identified only in limited portions 
S . aureus S . epiderm idis
24 48 72 24 48 72
0.25
0.50
0.75
1.00
Time (h)
B
io
fi
lm
  
s
u
rf
a
c
e
 c
o
v
e
ra
g
e
 r
a
ti
o
treatment
ctrl
R89BS
B.
Figure 5. Quantitative evaluatio of the biofilm surface coverage. Biofil coverage surface was
obtained by the analysis of a set of lo - agnification SEM images obtained collecting a backscattered
electron signal over a total surface of 29 mm2 at the SED center. R89BS-coated SEDs showed lower
coverage values with respect to control SEDs, irrespectively of the incubation ti e points (24 h, 48 h,
72 h) for both the tested Staphylococcus sp .
Qualitative analysis at higher magnification confirmed that the S. aureus biofilm appeared more
structured than that of S. epidermidis at 24 h in control SEDs. However, a three-dimensional architecture
and extracellular matrix were present in all control samples (untreated SEDs) at 48 h and 72 h of
incubation. A marked three-dimensional architecture typical of a mature biofilm was evident for both S.
aureus and S. epidermidis at 72 h on uncoated silicone discs. On the contrary, small and isolated aggregates
of bacteria were identified at 24 h in R89BS samples for both strains. More structured aggregates
were documented for S. aureus on treated SEDs at 48 h, showing elongated biofilm super-structures
that increased in size at 72 h. In contrast, S. epidermidis on treated SEDs showed a more uniform
cell distribution, with an increasing cell density at higher incubation times. The three-dimensional
development of biofilms for both Staphylococcus strains was very limited on R89BS-coated surfaces.
Typical features of a mature biofilm were identified only in limited portions of the R89BS-coated surfaces
at 72 h of incubation. A representative selection of SEM images showing biofilm micromorphology is
reported in Figure 6.
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Figure 6. Micromorphology of the biofilm on the SED surface. Coccoid microbial cells and an
extracellular matrix were present at the SED surface in different amounts according to incubation
time (24 h, 48 h, and 72 h) and type of sample (Ctrl: uncoated controls; R89BS: coated silicone discs).
A three-dimensional architecture was also revealed in control samples at incubation times longer than
24 h. I a es ere captured using scanning electron microscopy, high vacuum mode (primary electron
beam energy, 2 keV; original mag ificatio 5000×).
2.6. Cytotoxicity Analysis
Results from the R89BS cytotoxicity test on an MRC5 human normal lung fibroblast cell line are
shown in Figure 7. A cytotoxic effect (viability fro 41 to 64 ) as docu ented for direct exposure to
R89BS concentrations from 0.3 mg/mL to 1 mg/ L (p > 0.05 in comparison with positive control). On the
contrary, no significant cytotoxicity was found for concentrations less than or equal to 0.2 mg/mL.
Furthermore, no cytotoxic effect was detected for the coated SED eluates. MRC5 cell viability
after 48 h of exposure to the eluates obtained from both static and dynamic release conditions was
comparable to negative controls.
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3. Discussion
The extensive use of medical d vices improved patient quality of life but also exposed them to an
even higher risk of infection related to biofilm formation on these materials [22,32]. Bacteria attachment
on the surfaces of medical devices is the basis for serious healthcare-associated infections (HCAI)
correlated with significant morbidity and mortality [10]. In particular, S. aureus and S. epidermidis are
recognized as the most frequent causes of medical device-associated infections (DRIs) due to their
numerous virulence factors (e.g., production of toxins and biofilm formation) and their ability to evade
immune defenses [33].
New strategies to prevent biofilm formation or promote their dispersal via cell removal or killing
are, therefore, urgently required. Biosurfactants represent a new generation of anti-biofilm agents with
potential applicability in the pharmaceutical and biomedical fields [23,34].
These amphiphilic molecules, produced by several microorganisms as secondary metabolites,
are characterized by the presence of a hydrophilic and a hydrophobic portion, providing a peculiar
surface activity at the interface [35,36]. They can provide direct biocidal action against several
microorganisms by destabilizing cell membranes, altering their integrity and permeability [37–39].
Furthermore, BSs also indirectly interfere with cell adhesion and, consequently, with biofilm formation
by modulating microbial interaction with surfaces [40,41]. The advantages of biosurfactants over their
chemical counterpart are their specific action, low toxicity, high biodegradability, good performance in
extreme environmental conditions, and unique structures [24,42]. In particular, in the last few years,
the interest of the scientific community focused on rhamnolipids produced by P. aeruginosa [43–45].
In the present study, we provide evidence on the antimicrobial activity of the rhamnolipid biosurfactant
produced by P. aeruginosa 89 against S. aureus ATCC® 6538TM and S. epidermidis ATCC® 35984TM and
on R89BS anti-biofilm activity, in terms of both biofilm formation inhibition and biofilm dispersal.
In addition, the chemical composition of R89BS, the physicochemical characteristics of coated surfaces,
and cytotoxicity assays are presented.
The experimental setting was designed following a clinically oriented approach, using microbial
species and a coated substrate, which are relevant in the biomedical context. For both staphylococcal
strains, culture media and experimental conditions were chosen in order to promote their growth
and the development of structured biofilms. To mimic and test a simple medical device having
anti-biofilm properties, a rhamnolipid coating was realized on medical-grade silicone elastomer discs
using a pre-coating method based on R89BS physical adsorption at the silicone surface. A number
of complementary aspects of biofilm such as biomass, cell metabolic activity, biofilm disc coverage,
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and micro-structural characterization were considered to characterize and understand the coating
anti-biofilm effect.
There are two important strategies for potentially reducing early infections of implantable devices:
the reduction of the number of cells able to adhere to the surface and the delay of adhesion. R89BS is
able to satisfy both these needs through its antimicrobial and anti-adhesive activities.
Firstly, the antibacterial activity of R89BS against both planktonic and sessile cells was taken into
account in order to evaluate a possible use of this compound as an adjuvant of antibiotic treatment,
being active at non-cytotoxic concentrations. Previous studies showed, in fact, that treatments with
biosurfactants may facilitate the efficacy of combined antimicrobial drug therapies, which in most
cases are less efficient against biofilms [46–49].
When dispersed in a solution, R89BS showed antibacterial activity against staphylococcal
planktonic cells and promoted the effective removal of biofilms grown on SEDs. These results are in
agreement with previous literature findings on others rhamnolipid biosurfactants. Ndlovu et al. [25]
detected the pronounced antimicrobial activity of a rhamnolipid from P. aeruginosa ST5 against a broad
spectrum of opportunistic and pathogenic microorganisms by means of the agar disc susceptibility
test. Lotfabad et al. [26] observed a remarkable inhibitory effect of rhamnolipid mixtures (MR01 and
MASH1) produced by P. aeruginosa strains against Gram-positive bacteria with MIC values equal to
R89BS and comparable to antibiotics, posing them as a promising alternative to chemical drugs in the
treatment of bacterial infections. Similar results were also reported for some P. aeruginosa rhamnolipid
derivatives, which exhibited bactericidal activity against S. aureus ATCC 25923 and an S. aureus MRSA
strain with an MIC of 62.5 µg/mL, as well as an interesting biofilm dispersion activity [50].
In addition, and most relevant for implant applications, R89BS was shown to be an effective and
long-lasting anti-adhesive/anti-biofilm formation agent when used for coating medical-grade silicone.
To our knowledge, this is the first time that the anti-biofilm activity of a rhamnolipid-based coating
was evaluated on a silicone surface, obtaining significant anti-biofilm activities for incubation times up
to three days. Other studies showed that a prior adsorption of rhamnolipids on surfaces can reduce
bacterial adhesion and colonization [51–54]. De Araujo et al. [55] evaluated the potential of crude and
purified rhamnolipid produced by P. aeruginosa PA1 on controlling L. monocytogenes and P. fluorescens
biofilm formation with inhibitions up to 74% and 72% on polystyrene and on stainless-steel surfaces,
respectively. Rodrigues et al. [27] verified the efficacy of rhamnolipids in reducing the initial deposition
rate and the number of bacterial cells on voice prostheses after 4 h. In particular, a reduction in the
adhesion rate of 66% for S. salivarius and C. tropicalis and a reduction in the number of adhering cells of
48% on biosurfactant-conditioned silicone for S. epidermidis, S. salivarius, S. aureus, and C. tropicalis
were observed.
This study highlighted the potential of R89BS in preventing Gram-positive colonization of
silicone implantable devices. The anti-biofilm action of the R89BS coating can be explained by the
biosurfactant’s ability to modify the physicochemical properties of the silicone surface, increasing the
surface hydrophilicity and preventing the adhesion of bacteria. Moreover, the R89BS coating was
able to significantly interfere with biofilm formation and growth, depending on the specific microbial
strains. An equivalent inhibitory effect was obtained for both the biomass and the cell metabolic
activity of the S. aureus biofilm, whereas the metabolic activity was inhibited more than the biomass
build-up of the S. epidermidis biofilm. This can be explained by the fact that the biomass of S. epidermidis
ATCC® 35984TM is characterized by a prevalence of slime that may increase the amount of Crystal
Violet used to quantify the biomass.
Overall, it is remarkable that the R89BS coating was able to guarantee a comprehensive anti-biofilm
effect on both tested strains up to three days, while keeping a non-toxic effect on eukaryotic cells
exposed to its eluate. These aspects make the R89BS coating a promising candidate for developing
silicone medical devices with anti-biofilm properties.
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4. Materials and Methods
4.1. Strains
The biosurfactant-producing strain Pseudomonas aeruginosa 89 was isolated from a patient with
cystic fibrosis and stored at−80 ◦C in Tryptic Soy Broth (Biolife Italiana, Monza, Italy) with 25% glycerol.
Biofilm producer strains of Staphylococcus aureus ATCC® 6538TM and Staphylococcus epidermidis ATCC®
35984TM, stored at −80 ◦C in Brain Heart Infusion (Merck KGaA, Darmstadt, Germany) with 25%
glycerol, were used in biofilm assays.
4.2. Biosurfactant Production
A loopful of P. aeruginosa 89, from a Tryptic Soy Agar (TSA) overnight culture, was added to
40 mL of Nutrient Broth II (Sifin Diagnostics GmbH, Berlin, Germany) and incubated for 4 h at
37 ◦C at 140 rpm. Afterward, 24 mL of this culture was inoculated in 1.2 L of Siegmund–Wagner
medium (0.84 g of KH2PO4, 1.08 g of Na2HPO4, 2.40 g pf NaNO3, 0.48 g of MgSO4·7H2O, 0.12 g of
CaCl2·2H2O, 2.4 mL of a trace element solution, (0.40 g of FeSO4·7H2O, 0.30 g of MnSO4·H2O, and
0.12 g of (NH4)6Mo7O24·4H2O in 200 mL of distilled water), 36 mL of glycerol, and 1161.60 mL of
distilled water (pH adjusted to 6.7)) and incubated at 37 ◦C for five days at 120 rpm. At the end of
the incubation period, the broth culture was centrifuged (Sorvall RC-5B Plus Superspeed Centrifuge,
Fisher Scientific Italia, Milano, Italy) for 20 min at 6000 rpm. Free-cell supernatant was retrieved,
acidified using 6 M H2SO4 at pH 2.2, and stored overnight at 4 ◦C. Eventually, biosurfactant R89
(R89BS) was extracted three times with ethyl acetate (Merck KGaA, Darmstadt, Germany), and the
organic phase was evaporated to dryness under vacuum conditions.
4.3. Chemical Characterization of Biosurfactant R89
An aliquot of the crude biosurfactant extract was dissolved in methanol to obtain a 1 mg/mL stock
solution. Freshly prepared working solutions were made by diluting the stock solution with methanol
to 10 µg/mL solutions.
Mass spectrometry analyses were done on an LCQ DECA XP Plus (Thermo Finnigan, San Jose, CA,
USA) IonTrap mass instrument equipped with an ESI source. Samples (10 µg/mL solutions) were injected
with a syringe at 5 mL/min flow rate. Source voltage and capillary voltage were at 5.0 kV and 18 V in
negative mode. The capillary temperature was maintained at 300 ◦C, and nitrogen was used as nebulizing
gas at 50 arbitrary units. Data were acquired in negative MS total ion scan mode (mass scan range m/z
100–1000) and MS/MS product ion scan mode with normalized collision energy (nce%) optimized for each
precursor ion selected: m/z 475, 531, and 649, 27%, 503, 25%, 677, 29%, and 621, 31%.
4.4. Antimicrobial Test on Planktonic Cells
The susceptibility of Staphylococcus planktonic cells to biosurfactant R89 was determined in
96-well microtiter plates using the broth dilution method according to Wiegand et al. [56] with some
modifications. The tested concentration of R89BS ranged from 0.03 to 0.25 mg/mL. Bacterial suspensions
(5 × 105 CFU/mL) were inoculated in Mueller-Hinton Broth (Sifin Diagnostics GmbH, Berlin, Germany)
in the presence of different R89BS concentrations. In control wells, the inoculum was mixed with an
equal volume of PBS. Plates were incubated at 37 ◦C for 16–20 h. Blank wells were also included.
The minimal inhibitory concentration (MIC) of R89BS was determined as the lowest concentration of the
molecule that inhibited the growth of the tested strains as observed with the unaided eye. The observed
vancomycin MICs (S. aureus MIC 1 µg/mL; S. epidermidis MIC 2 µg/mL), in line with the EUCAST
International MIC distribution Reference Database (https://mic.eucast.org/Eucast2/SearchController/),
were used as a reference during the evaluation of the antimicrobial activity of R89BS.
Finally, absorbance (A) at 595 nm was measured for each well (Ultramark Microplate Imaging
System, Bio-Rad Laboratories S.r.l., Segrate, Italy), data were normalized with respect to the blank
value, and the percentage of bacterial growth reduction was calculated as indicated in Section 4.10.
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Assays were conducted in triplicate and repeated on three different days.
4.5. Preparation of Medical-Grade Silicone Substrate
Discs of 10 mm in diameter and 1.5 mm in thickness were cut from medical-grade silicone sheets
(TECNOEXTR s.r.l, Palazzolo sull’Oglio, Italy). Cleaning and sterilization of silicone elastomeric discs
(SEDs) were performed as indicated in Ceresa et al. [57]. Briefly, SEDs were washed with a 1.4% (v/v)
RBSTM 50 solution (Sigma-Aldrich), sonicated for 5 min, and rinsed twice in Milli-Q water. SEDs were
then dipped in methanol (99%), sonicated for 5 min, and rinsed as above. Afterward, the material
was sterilized by autoclave (121 ◦C, 15 min), dried at 37 ◦C for 20 h, and moved aseptically into
24-well plates.
4.6. Disruption of Pre-Formed Biofilms
For each strain, appropriate inoculum density, media, and growth conditions for biofilm formation
were used. In particular, for S. aureus, glucose was added as a biofilm formation inducer, whereas,
for S. epidermidis, cultivation under shaking was selected to promote slime production.
Bacterial suspensions were prepared at a cell density of 1 × 107 CFU/mL in Tryptic Soy Broth
(TSB) for S. epidermidis or TBS supplemented with 1% glucose (TSBG) for S. aureus. Experiments were
conducted on a 24-well polystyrene plate, placing one SED per well. Each SED was submerged in
1 mL of inoculum and incubated at 37 ◦C for 24 h at 160 rpm for S. epidermidis or in static conditions
for S. aureus. SEDs with biofilms formed on the surface were then carefully transferred into new
plates, treated with different concentrations of R89BS (0.06–2 mg/mL), and incubated for a further 24 h.
The dislodging activity of R89BS was evaluated by means of the MTT reduction assay detailed below.
Assays were conducted in triplicate and repeated on two different days.
4.7. Silicone Surface Coating and Physicochemical Characterization
BS coating via physical adsorption was obtained by immersing silicone coupons or SEDs in 1 mL
of a 2 mg/mL R89BS solution (R89BS-coated SEDs) for 24 h at 37 ◦C at 180 rpm. Control coupons
or SEDs were immersed in 1 mL of PBS only. The R89BS solution was aspirated; then, SEDs were
transferred to new plates and dried under a laminar flow cabinet (Heraeus Herasafe HS18, Kendro
Laboratory Products, Hanau, Germany).
Contact angle was measured by the Whilelmy method using a Cahn DCA 322 microbalance
(Cahn Scientific, Irvine, CA, USA) and Milli-Q® (MerkMillipore, Burlington, MA, USA) water at room
temperature as the average value from five samples.
In order to detect compositional surface modifications, attenuated total reflectance
Fourier-transform infrared spectroscopy (ATR-FTIR, FT-IR Spectrometer Frontier, PerkinElmer, Milan,
Italy) was performed on control SEDs and R89BS-coated SED samples using a Perkin Elmer Spectrum.
One spectrometer was equipped with a Diamant crystal. IR spectra were collected in the 4000 and
600 cm−1 wavenumber range at a resolution of 4 cm−1 and averaged over 32 scans. Spectra were
analyzed by Spectrum software (PerkinElmer, Milan, Italy).
4.8. Anti-Biofilm Assays
Bacterial suspensions were prepared at a cell density of 1 × 107 CFU/mL in TSB for S. epidermidis
or TBS + 1% glucose (TSBG) for S. aureus. R89BS-coated SEDs and control SEDs were submerged in
1 mL of bacterial suspension and incubated at 37 ◦C at 160 rpm (S. epidermidis) or in static conditions
(S. aureus) for 24, 48, and 72 h. Every 24 h, SEDs were transferred onto new plates containing fresh
media. At the end of the incubation period, the growth medium was removed, and SEDs were gently
washed twice with PBS to remove non-adherent cells.
Samples were prepared in triplicate and repeated on two different days.
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4.8.1. Biofilm Quantification
The anti-biofilm effect of R89BS-coated SEDs was quantitatively determined by Crystal Violet
(CV) staining (biofilm biomass) and an MTT (3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium
bromide) reduction assay (cell metabolic activity).
For the evaluation of total biomass, biofilms were dried and stained with 1 mL of CV solution (0.2%)
for 10 min. Blank SEDs (without biofilm) were also included. SEDs were washed with distilled water to
remove dye excess and air-dried. The CV amount of each SED was determined spectrophotometrically
after solubilization in 1 mL of acetic acid (33% in water).
For the determination of cell metabolic activity, biofilms were dipped in 1 mL of 0.3% MTT
solution supplemented with 0.01% glucose and 1 µM menadione. After 30 min of incubation at 37 ◦C
in static conditions, formazan crystals into biofilms were dissolved with 1 mL of a dimethyl sulfoxide
(DMSO)/0.1 M glycine buffer (pH 10.2) solution (7:1).
A570 of the solutions was measured (Victor3VTM, Perkin Elmer, Milan, Italy). Data were normalized,
and the percentage of biofilm reduction was calculated with the formula explained in Section 4.10.
4.8.2. Scanning Electron Microscopy Analysis of Bacterial Biofilms
A quantitative and qualitative analysis of biofilms was also performed by scanning electron
microscopy (SEM) adapting the protocol described in Ceresa et al. [58]. Quantitative SEM analysis was
conducted with a XL30 ESEM FEG (Fei, Eindhoven, The Netherland) scanning electron microscope
at a 15-kV beam voltage in low-vacuum mode, using a vapor pressure of 1.4 Torr to avoid excessive
dehydration of the biofilm and the need for applying a conductive coating. A set of nine different fields
of view for each SED was obtained by collecting the backscattered electrons signal at a magnification
of 60×, thus guaranteeing the observation of a total area of 29 mm2 at the silicone disc center.
To distinguish between biofilm-covered surface and exposed silicone, high-resolution digital images
(1936 × 1452 pixels) were acquired and then thresholded using a semi-automated routine implemented
in ImageJ (National Institutes of Health, Bethesda, MD, USA) according to the protocol used by Bressan
et al. [59]. Percentage area of the silicone disc covered by bacterial biofilms (BA%) was calculated as
explained in Section 4.10. Assays were carried out in triplicate.
Qualitative characterization of biofilm micromorphology and architecture was investigated using
a Quanta 200F FEG (Fei, Eindhoven, The Netherlands ) scanning electron microscope in high-vacuum
mode after coating the samples with a 10-nm layer of gold with a sputter coater (Emitech K500X,
Quorum Technologies, Laughton, UK). Images at 5000×magnification were acquired to detect fine
morphological details of cells and the extracellular matrix by collecting the secondary electron signal
with a primary beam energy of 2 keV. Possible artefacts due to the sample preparation process were
considered according to indications provided by Hrubanova et al. [60].
4.9. R89BS and R89BS-Coated SED Cytotoxicity
The potential cytotoxicity of R89BS and R89BS-coated SEDs was evaluated by a lactate
dehydrogenase (LDH) assay (ISO 10993) (TOX7 In Vitro Toxicology Assay Kit, Sigma-Aldrich,
Darmstadt, Germany), using normal lung fibroblasts (MRC5), according to TOX7 operative
procedures [61]. The cell line was maintained in modified Eagle’s medium (MEM) supplemented with
10% fetal calf serum (FCS), l-glutamine (2 mM), sodium pyruvate (1mM), 1% non-essential amino acids,
and 1% antibiotics at 37 ◦C, 5% CO2, and 95% relative humidity. R89BS-coated SEDs were immerged in
fresh cell culture medium at 37 ◦C for 24 h in static or dynamic conditions (obtained by orbital shaking at
1 Hz to improve biosurfactant removal from the surface). At the same time, cells were seeded in 96-well
tissue culture plates and cultured in standard medium until about 70% confluence (24 h). Afterward,
the growth medium was removed and replaced with the medium containing R89BS solutions at
different concentrations (1.0, 0.5, 0.4, 0.3, 0.2, 0.1 mg/mL) or the conditioned surface-contacting medium
(200 µL/well). The cytotoxic effect was measured on the basis of the amount of LDH released by cells
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after 48 h of exposure. The positive control for cytotoxicity constituted fully lysate cells (0.5% Triton X),
while cells in reduced medium without surfactant constituted the negative control. LDH level was
evaluated by light absorbance at 490 nm (Tecan Spark 10 M). Assays were carried out in quintuplicate.
4.10. Data Analysis and Statistics
In tables and graphs, data were reported as means ± standard deviation. Confidence intervals
(95%) of the ratio between values obtained from the control SEDs (Ctrl) and R89BS-coated SEDs (R89BS)
were calculated from the corresponding confidence intervals for logCtrl − logR89BS.
The inhibition percentages (INHIBIT%) of bacterial growth, biofilm formation, and biofilm
disruption were calculated with the following formula:
INHIBIT% =
(
1− T
Ctrl
)
× 100 (1)
where T is the absorbance value of treated samples, and Ctrl is the absorbance value of the control.
The percentage of the SED area covered by biofilms (BA%) was calculated as follows:
BA% =
(
dark pixel
total pixel number
)
× 100 (2)
where dark pixels represent the biofilm-covered surface, and total pixel number represents the total
SED surface.
The percentage of cytotoxicity (CYTOTOX%) was calculated as follows:
CYTOTOX% =
( AR89BS −Aneg.Ctrl
Apos.Ctrl −Aneg.Ctrl
)
× 100 (3)
where AR89BS is the absorbance of samples treated with R89BS; Apos.Ctrl is the absorbance of positive
control (0.5% Triton X), and Aneg.Ctrl is the absorbance of negative control (growth medium).
Statistical analyses and graphics were elaborated by means of the statistical program R, 3.5.2.
(R Development Core Team, http://www.R-project.org). One-way ANOVA followed by Tukey post hoc
test was performed to study the effect of the different concentrations of R89BS (considered as factor
variables) on pre-formed biofilms of each Staphylococcus strain and to evaluate the significance of data
in the LDH cytotoxicity assay in comparison to positive and negative controls. Two-way ANOVA and
a t-test were performed to investigate the effect of R89BS-coated SEDs on each Staphylococcus strain
biofilm formation. Results were considered to be statistically significant when p < 5 × 10−2.
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